Key facts
- This page summarizes Peter Maag's Form 3 filing for Kyverna Therapeutics, Inc. (KYTX).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 07 Feb 2024, 21:55.
Peter Maag - 07 Feb 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- KYTX
- Reported as of
- 07 Feb 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 07 Feb 2024, 21:55:36 UTC
- Prior SEC filing
- 05 Jan 2024
- Next SEC filing
- 08 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Ryan Jones, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Maag filed Form 3 for Kyverna Therapeutics, Inc. (KYTX) on 07 Feb 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KYTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 58,220
- Date
- 07 Feb 2024
- Ownership
- Direct
KYTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 349,321
- Date
- 07 Feb 2024
- Ownership
- By The Maag Family Irrevocable Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KYTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 07 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 329,590
- Exercise price
- $4.83
- Footnotes
- F1
KYTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 07 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,098
- Exercise price
- $4.33
- Footnotes
- F2
KYTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 07 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 989,743
- Exercise price
- $3.15
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Footnote F2
25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Footnote F3
25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
SEC remarks
Exhibit 24 - Power of Attorney